Andromeda Biotech

Andromeda Biotech is developing an innovative new treatment for type 1 diabetes.

The company’s lead produat, Diapep 277®, is currently in phase 3 trials, and is poised to revolutionize the treatment, and longterm prognosis of this incurable, degenerative disease.

Leave a Comment

You must be logged in to post a comment.